Journal of Experimental & Clinical Cancer Research

OCT 23, 2026 · JOURNAL ARTICLE

ERG inhibition selectively sensitizes ERG-positive prostate cancer to radiation through DNA repair vulnerabilities and enhances response to androgen receptor inhibitors

Journal of Experimental & Clinical Cancer Research

Abstract Background ERG overexpression, driven by TMPRSS2-ERG gene fusion, occurs in ~ 50% of prostate cancers (PCa) and defines a molecular subtype with distinct therapeutic vulne

OCT 22, 2026 · JOURNAL ARTICLE

Tetrandrine stabilizes NCOA4 to promote ferritinophagy-mediated ferroptosis and enhance antitumor immunity in NSCLC

Journal of Experimental & Clinical Cancer Research

Abstract Background Natural products are an important source of anticancer agents. Tetrandrine is a natural bisbenzylisoquinoline alkaloid, but how it regulates ferritinophagy and

OCT 21, 2026 · JOURNAL ARTICLE

Baseline and early changes in serum proteomic profiles predict anti-tumor activity in patients with advanced HPV-associated malignancies treated with novel combination immunotherapy

Journal of Experimental & Clinical Cancer Research

Abstract Background Patients with advanced human papillomavirus (HPV)–associated malignancies who do not respond to immune checkpoint blockade have limited treatment options. Combi

OCT 20, 2026 · JOURNAL ARTICLE

MiR-22-3p shapes glioblastoma radiation resistance and downregulates the DNA demethylase tumor suppressor TET1

Journal of Experimental & Clinical Cancer Research

Abstract Glioblastoma (GB) is an aggressive brain tumor characterized by marked radioresistance and poor clinical outcomes. MicroRNAs (miRNAs) are key post-transcriptional regulato

OCT 7, 2026 · JOURNAL ARTICLE

Reprogramming the tumor immune landscape through SPP1 targeting

Journal of Experimental & Clinical Cancer Research

Abstract Beyond its canonical roles in bone mineralization and extracellular matrix remodeling, secreted phosphoprotein 1 (SPP1) has emerged as a central regulator of the tumor mic

OCT 6, 2026 · JOURNAL ARTICLE

Multimodal analysis identifies a fibroblast subtype enriched in EGFR-mutant NSCLC and its spatial niches

Journal of Experimental & Clinical Cancer Research

Abstract Background The tumor microenvironment (TME) in non-small cell lung cancer (NSCLC) exhibits heterogeneity across distinct oncogenic driver mutations, but whether specific s

SEP 29, 2026 · JOURNAL ARTICLE

Disitamab vedotin triggers ferroptosis to activate CD8+ T-cell antitumor immunity in HER2-expressing breast cancer

Journal of Experimental & Clinical Cancer Research

Abstract Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is highly aggressive and is associated with poor prognosis after metastasis or recurrence. The devel

SEP 24, 2026 · JOURNAL ARTICLE

LukS-PV targets human C5aR1 to reprogram tumor-associated macrophages and potentiate immunotherapy in hepatocellular carcinoma

Journal of Experimental & Clinical Cancer Research

Abstract Background Immune checkpoint inhibitors (ICIs) benefit only a subset of patients with hepatocellular carcinoma (HCC), largely because of an immunosuppressive tumor microen